Sanofi
4,122.20
-37.20(-0.89%)
Market Cap₹9,493.68 Cr
PE Ratio24.16
IndustryHealthcare
Company Performance:
1D-0.89%
1M-3.48%
6M-31.42%
1Y-31.64%
5Y-49.77%
View Company Insightsright
More news about Sanofi
27Oct 25
Sanofi India Shareholders Approve Deepak Arora as Managing Director with 94.70% Votes
Sanofi India Limited has successfully completed the shareholder approval process for Deepak Arora's appointment as Managing Director, with the postal ballot yielding 94.70% votes in favour. The remote e-voting process, conducted from November 18 to December 17, 2025, also approved his appointment as Director with 99.84% support, formally confirming the leadership transition that began in October 2025.
25Sept 25
Sanofi India Announces Key Leadership Changes in Company Secretary Role
Sanofi India Limited (SIL) has announced changes in its Company Secretary and Compliance Officer position. Arjun Thakkar will resign effective September 30, 2025, to pursue a new role within the Sanofi Group. Haresh Vala, with over two decades of experience in corporate secretarial and compliance functions, will take over the position from October 1, 2025. Vala, an Associate Member of the Institute of Company Secretaries of India, will also be authorized to determine the materiality of events and make disclosures to Stock Exchanges.
02Aug 25
Sanofi India Reports Mixed Q2 2025 Results: Net Sales Decline, Operating Profit Rises
Sanofi India Limited (SIL) announced Q2 2025 results with a 9% decline in net sales but a 6% increase in operating profit year-to-date. The company's diabetes portfolio, including Soliqua® and Toujeo®, performed well in the domestic market. Strategic partnerships in Cardiovascular and Central Nervous System segments met expectations. Export sales were negatively impacted by non-recurring Consumer Healthcare product sales and planned discontinuation of the Zentiva portfolio. Management remains focused on operational efficiency and expanding access to established and innovative therapies across India.
31Jul 25
Sanofi Reports Q2 Results, Announces Leadership Changes and Strategic Partnership
Sanofi's Q2 financial results show a decline in revenue and net profit compared to Q1 and Q2 of the previous year. Revenue from operations was ₹4,063.00 million, down from ₹5,359.00 million in Q1. Net profit stood at ₹695.00 million, a decrease from ₹1,195.00 million in Q1. The company announced the retirement of Ms. Renee Amonkar and the appointment of Mr. Mahadev Gawade as the new Site Director - Goa. Sanofi also entered into a promotion and distribution agreement with Emcure Pharmaceuticals Limited for its Oral Anti-diabetic business products.
14May 25
Sanofi India: Q4 FY25 Shows Mixed Results with EBITDA Growth Despite Profit Decline
Sanofi India's Q4 FY25 results show a 25% YoY increase in EBITDA to ₹171.90 crore and an EBITDA margin rise to 32.10%. Revenue grew 5% YoY to ₹535.90 crore, with net sales up 4%. However, net profit declined 12.50% YoY to ₹119.50 crore. The launch of Soliqua® contributed to growth, highlighting operational efficiency improvements despite profit challenges.
28Feb 25
Sanofi India: Q4 Profit Surges 31%, Announces ₹117 Dividend
Sanofi India Limited (SIL) announced strong Q4 2024 results with revenue increasing 10% year-over-year to ₹515 crore and net profit jumping 31% to ₹91.3 crore. The growth was driven by a robust diabetes portfolio, successful launch of Soliqua®, and improved operational efficiency. The company's operating profit rose by 21%. The Board recommended a dividend of ₹117 per equity share for FY2024.
27Feb 25
Sanofi India Reports Mixed Q3 2024 Results with Revenue Growth and Profit Decline
Sanofi India Limited announced its Q3 2024 financial results, showing a 9.8% increase in revenue to ₹5,150 million, but a 33.8% decrease in net profit to ₹913 million. EBITDA grew by 18.5% to ₹1,180 million, with the EBITDA margin improving to 22.98%. Profit Before Tax increased by 14.8% to ₹1,140 million. An exceptional item of ₹80 million was noted, potentially impacting overall profit figures.
Sanofi
4,122.20
-37.20
(-0.89%)
1 Year Returns:-31.64%
Industry Peers
Sun Pharmaceutical
1,729.90
(-1.75%)
Divis Laboratories
6,616.50
(+0.24%)
Torrent Pharmaceuticals
3,963.40
(-1.56%)
Cipla
1,465.70
(+0.35%)
Dr Reddys Laboratories
1,210.10
(+0.27%)
Lupin
2,182.20
(-0.40%)
Mankind Pharma
2,200.80
(-2.67%)
Zydus Life Science
894.90
(-1.39%)
Aurobindo Pharma
1,198.70
(-0.61%)
Alkem Laboratories
5,799.00
(+0.10%)